Nga ra mắt thuốc điều trị COVID-19 đầu tiên được cấp phép

Ngày 11/6, Nga đã cho ra mắt loại thuốc điều trị bệnh viêm đường hô hấp cấp COVID-19 đầu tiên được cấp phép với tên gọi Avifavir, trong bối cảnh số ca mắc bệnh ở nước này đã vượt quá mốc 500.000 người.

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

Bình luận

Xin vui lòng gõ tiếng Việt có dấu

Tin cùng chuyên mục

Mỹ tranh luận về phân phối lợi ích từ AI

Mỹ tranh luận về phân phối lợi ích từ AI

Thế giới
(Baothanhhoa.vn) - Tranh luận về việc phân phối lợi ích từ trí tuệ nhân tạo (AI) đang gia tăng tại Mỹ, trong bối cảnh công nghệ này phát triển nhanh chóng và có thể làm thay đổi sâu sắc thị trường lao động. Nhiều đề xuất về quỹ quốc gia, thu nhập cơ bản và chia sẻ lợi...
Chứng nhận tín nhiệm mạng
Việt Long Phần mềm tòa soạn
hội tụ thông minh